The short version of Reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
==== Effects on spermatogenesis and fertility ==== Spermatogenesis and male fertility are dependent on FSH, LH, and high levels of testosterone within the testicles. LH does not seem to be involved in spermatogenesis outside of its role in inducing production of testosterone by the Leydig cells in the seminiferous tubules (which make up approximately 80% of the bulk of the testes), whereas this is not the case for FSH, which is importantly involved. In accordance with the fact that the testes are the source of 95% of circulating testosterone in the body, local levels of testosterone inside of the testes are extremely high, ranging from 20- to 200-fold higher than circulating concentrations. Moreover, high levels of testosterone within the testes are required for spermatogenesis, although only a small fraction (5–10%) of normal levels appears to actually be necessary for spermatogenesis. Unlike with antigonadotropic antiandrogens like CPA and GnRH analogues, it has been reported that bicalutamide monotherapy (at 50 mg/day) has very little or no effect on the ultrastructure of the testes and on spermatogenesis in men even after long-term therapy (>4 years). This may be explained by the extremely high local levels of testosterone in the testes, in that it is likely that systemic bicalutamide therapy is unable to achieve concentrations of the drug within the testes that are able to considerably block androgen signaling in this part of the body.
=== Africa === Fake antimalarial medication has been threatening efforts to control malaria in Africa, including the development of antimalarial resistance. Other medicines have been documented to be of dangerously poor quality. In October 2022, the deaths of at least 70 children in Gambia were linked to cough syrups manufactured in India, which had high levels of diethylene glycol and ethylene glycol. There were delays in government response, despite doctors pressing for this. In 2011, according to the World Health Organization (WHO), 64% of Nigeria's imported antimalarial medication drugs were fake. By 2023, the problem of substandard and falsified medicines had lessened somewhat since the peak. Nigeria is Africa's largest drugs market, and over 70% of its drugs are imported from India and China, considered the "biggest source of fakes." One response has been attempts to bolster domestic production of medicines, but challenges include insecurity and unstable electricity. There have been investments in technologies to increase detection and verification of poor-quality medicines. In 2018, Tramadol, a powerful and addictive opioid, became a major problem. A huge black market has emerged, and an increasing number of addicts overdose and die.
Soils contaminated by heavy metals can be remediated by one or more of the following technologies: isolation; immobilization; toxicity reduction; physical separation; or extraction. Isolation involves the use of caps, membranes or below-ground barriers in an attempt to quarantine the contaminated soil. Immobilization aims to alter the properties of the soil so as to hinder the mobility of the heavy contaminants. Toxicity reduction attempts to oxidise or reduce the toxic heavy metal ions, via chemical or biological means into less toxic or mobile forms. Physical separation involves the removal of the contaminated soil and the separation of the metal contaminants by mechanical means. Extraction is an on or off-site process that uses chemicals, high-temperature volatization, or electrolysis to extract contaminants from soils. The process or processes used will vary according to contaminant and the characteristics of the site.
=== 1H—13C HSQC === This experiment provides correlations between a carbon and its attached protons. The constant time (CT) version of 1H—13C HSQC is normally used as it circumvents the issue of splitting of signal due to homonuclear 13C—13C J couplings which reduces spectral resolution. The "constant time" refers to the entire evolution period between the two INEPT steps which is kept constant in this experiment. If this evolution period is set to be the inverse of the J-coupling constant, then the sign of the magnetization of those carbons with an odd number of aliphatic carbon attached will be opposite to those with an even number. For example, if the Cβ of leucine appears as a positive peak (2 aliphatic carbons attached), then the Cγ (3 aliphatic carbons attached) and Cα (1 aliphatic carbons attached) would appear negative.
== Discovery == The technique was invented in 1955 by Grant Henry Lathe and Colin R Ruthven, working at Queen Charlotte's Hospital, London. They later received the John Scott Award for this invention. While Lathe and Ruthven used starch gels as the matrix, Jerker Porath and Per Flodin later introduced dextran gels; other gels with size fractionation properties include agarose and polyacrylamide. A short review of these developments has appeared. There were also attempts to fractionate synthetic high polymers; however, it was not until 1964, when J. C. Moore of the Dow Chemical Company published his work on the preparation of gel permeation chromatography (GPC) columns based on cross-linked polystyrene with controlled pore size, that a rapid increase of research activity in this field began. It was recognized almost immediately that with proper calibration, GPC was capable to provide molar mass and molar mass distribution information for synthetic polymers. Because the latter information was difficult to obtain by other methods, GPC came rapidly into extensive use.
Sources: en.wikipedia.org
== Early life == Flay was born on December 10, 1964, in New York City, to Bill and Dorothy Barbara (McGuirk) Flay. He was raised on the Upper East Side of Manhattan. He is a fourth-generation Irish American and was raised Catholic, attending denominational schools. At age 8, Flay asked for an Easy-Bake Oven for Christmas. His father thought that a G.I. Joe would be more appropriate. Despite his father's objections, he received them both.
==== Hybrid Closed Loop (HCL) / Advanced Hybrid Closed Loop (AHCL) ==== Hybrid closed loop (HCL) systems further expand on the capabilities of PLGS systems by adjusting basal insulin delivery rates both up and down in response to values from a continuous glucose monitor. Through this modulation of basal insulin, the system is able to reduce the magnitude and duration both hyperglycemic and hypoglycemic events. Users still must initiate manual mealtime boluses. Advanced hybrid closed loop systems have advanced algorithms. Fully Closed Loop (FCL) Fully or full closed loop (FCL) systems adjust insulin delivery in response to changes in glucose levels without requiring input by users for mealtime insulin or announcements of meals.
=== Bone regeneration === EGF plays an enhancer role on the osteogenic differentiation of dental pulp stem cells (DPSCs) because it is capable of increasing extracellular matrix mineralization. A low concentration of EGF (10 ng/ml) is sufficient to induce morphological and phenotypic changes. These data suggests that DPSCs in combination with EGF could be an effective stem cell-based therapy to bone tissue engineering applications in periodontics and oral implantology.
=== Patent litigation === The PEGylated lipid nanoparticle drug delivery (LNP) system of the mRNA vaccine known as mRNA-1273 has been the subject of ongoing patent litigation with Arbutus Biopharma, from whom Moderna had previously licensed LNP technology. On 4 September 2020, Nature Biotechnology reported that Moderna had lost a key challenge in the ongoing case.
Sources: en.wikipedia.org
The Ministry of the Interior stripped the Communist Party of Ukraine, the Communist Party of Ukraine (renewed), and the Communist Party of Workers and Peasants of their right to participate in elections and stated it was continuing the court actions that started in July 2014 to end the registration of communist parties in Ukraine. By 16 December 2015, these three parties had been banned in Ukraine; the Communist Party of Ukraine appealed the ban to the European Court of Human Rights.
Upon rewarming, the kidney was transplanted successfully into a rabbit, with complete functionality and viability, able to sustain the rabbit indefinitely as the sole functioning kidney. In 2000, FM-2030 became the first person to be successfully vitrified posthumously.
Baby monitor – a crib-side appliance for parents of infants that transmits the baby's sounds to a receiver carried by the parent, so they can monitor the baby while they are in other parts of the house. The wavebands used vary by region, but analog baby monitors generally transmit with low power in the 16, 9.3–49.9 or 900 MHz wavebands, and digital systems in the 2.4 GHz waveband. Many baby monitors have duplex channels so the parent can talk to the baby, and cameras to show video of the baby. Wireless microphone – a battery-powered microphone with a short-range transmitter that is handheld or worn on a person's body which transmits its sound by radio to a nearby receiver unit connected to a sound system. Wireless microphones are used by public speakers, performers, and television personalities so they can move freely without trailing a microphone cord. Traditionally, analog models transmit in FM on unused portions of the television broadcast frequencies in the VHF and UHF bands. Some models transmit on two frequency channels for diversity reception to prevent nulls from interrupting transmission as the performer moves around. While some consumer models use digital modulation in the 900 MHz, 2.4 GHz, or 6 GHz ISM bands, most professional wireless microphone and in-ear monitor (IEM) systems operate in the UHF TV band (typically 470–702 MHz). Modern developments include Wireless Multichannel Audio Systems (WMAS), which utilize wideband transmission to support high channel density within a single radio frequency carrier.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.